Halozyme Therapeutics, Inc. (NASDAQ:HALO) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) have earned an average rating of “Moderate Buy” from the seven analysts that are currently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $53.29.

Several analysts recently issued reports on the stock. HC Wainwright boosted their price objective on shares of Halozyme Therapeutics from $48.00 to $50.00 and gave the company a “buy” rating in a report on Wednesday, February 21st. TheStreet lowered Halozyme Therapeutics from a “b-” rating to a “c+” rating in a research report on Monday, January 22nd. Morgan Stanley lowered their price target on Halozyme Therapeutics from $61.00 to $59.00 and set an “overweight” rating for the company in a research report on Tuesday, December 26th. The Goldman Sachs Group cut their price objective on Halozyme Therapeutics from $45.00 to $40.00 and set a “neutral” rating on the stock in a report on Thursday, January 18th. Finally, JMP Securities restated a “market outperform” rating and set a $72.00 target price on shares of Halozyme Therapeutics in a report on Wednesday, February 21st.

Halozyme Therapeutics Stock Performance

Halozyme Therapeutics stock opened at $38.61 on Friday. The firm has a 50 day simple moving average of $39.22 and a 200-day simple moving average of $37.77. The stock has a market cap of $4.91 billion, a price-to-earnings ratio of 18.30, a price-to-earnings-growth ratio of 0.47 and a beta of 1.25. The company has a debt-to-equity ratio of 17.89, a current ratio of 6.64 and a quick ratio of 5.50. Halozyme Therapeutics has a 1-year low of $29.85 and a 1-year high of $45.00.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings data on Tuesday, February 20th. The biopharmaceutical company reported $0.75 EPS for the quarter, missing analysts’ consensus estimates of $0.77 by ($0.02). The business had revenue of $230.04 million during the quarter, compared to analyst estimates of $235.25 million. Halozyme Therapeutics had a net margin of 33.96% and a return on equity of 248.20%. On average, analysts expect that Halozyme Therapeutics will post 3.33 EPS for the current year.

Insider Buying and Selling

In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 10,000 shares of the stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $41.64, for a total value of $416,400.00. Following the sale, the senior vice president now owns 156,558 shares of the company’s stock, valued at approximately $6,519,075.12. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 2.40% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Hsbc Holdings PLC increased its holdings in shares of Halozyme Therapeutics by 35.0% in the 3rd quarter. Hsbc Holdings PLC now owns 78,404 shares of the biopharmaceutical company’s stock valued at $3,006,000 after acquiring an additional 20,346 shares during the last quarter. Allspring Global Investments Holdings LLC raised its holdings in Halozyme Therapeutics by 174.5% during the third quarter. Allspring Global Investments Holdings LLC now owns 887,274 shares of the biopharmaceutical company’s stock worth $33,894,000 after purchasing an additional 563,989 shares in the last quarter. Aurora Investment Counsel purchased a new stake in shares of Halozyme Therapeutics during the 3rd quarter worth approximately $1,347,000. Campbell & CO Investment Adviser LLC purchased a new stake in shares of Halozyme Therapeutics during the 3rd quarter worth approximately $591,000. Finally, Boston Partners acquired a new position in shares of Halozyme Therapeutics in the 3rd quarter valued at $3,186,000. Institutional investors and hedge funds own 97.79% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.